Metastatic Urothelial Carcinoma of the Bladder with Lymph Node-only Metastasis Treated with M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) has a Better Survival than GC (Gemcitabine and Cisplatin)

Metastatic Urothelial Carcinoma of the Bladder with Lymph Node-only Metastasis Treated with M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) has a Better Survival than GC (Gemcitabine and Cisplatin)

Background: Previous studies demonstrated that GC (gemcitabine and cisplatin) provided a similar survival advantage as M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for urothelial carcinoma of the bladder (UCB), and had a better safety profile and improved tolerability. However, no cl...

Full description

Bibliographic Details
Main Authors: Meng-Che Hsieh, Po-Hui Chiang, Kun-Ming Rau, Yen-Yang Chen, Yo-Li Su, Cheng-Hua Huang
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2014-12-01
Series:Journal of Cancer Research and Practice
Subjects:
urothelial carcinoma of the bladder
lymph node-only metastasis
M-VAC
GC
survival benefits
response rate
Online Access:http://www.sciencedirect.com/science/article/pii/S2311300616300441

Internet

http://www.sciencedirect.com/science/article/pii/S2311300616300441

Similar Items